K
Kirsty Morrison
Researcher at The Royal Marsden NHS Foundation Trust
Publications - 7
Citations - 397
Kirsty Morrison is an academic researcher from The Royal Marsden NHS Foundation Trust. The author has contributed to research in topics: Prostate cancer & Randomized controlled trial. The author has an hindex of 3, co-authored 6 publications receiving 185 citations. Previous affiliations of Kirsty Morrison include Institute of Cancer Research.
Papers
More filters
Journal ArticleDOI
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Douglas Brand,Douglas Brand,Alison Tree,Alison Tree,Peter Ostler,Hans van der Voet,Andrew Loblaw,William Chu,Daniel Ford,Shaun Tolan,Suneil Jain,Alexander G.R. Martin,John Staffurth,Philip Camilleri,Kiran Kancherla,John Frew,Andrew K Chan,Ian S. Dayes,Daniel Henderson,Stephanie Brown,Clare Cruickshank,Stephanie Burnett,A. Duffton,Clare Griffin,Victoria Hinder,Kirsty Morrison,Kirsty Morrison,O. Naismith,Emma Hall,Nicholas van As,Nicholas van As,D Dodds,E Lartigau,S Patton,Alan J. Thompson,Mathias Winkler,P Wells,T Lymberiou,Daniel Saunders,M Vilarino-Varela,P Vavassis,Theodoros Tsakiridis,R Carlson,George Rodrigues,Jacob Tanguay,S Iqbal,Scott C. Morgan,A Mihai,A Li,O Din,Miguel Panades,R Wade,Yvonne Rimmer,J Armstrong,N Oommen +54 more
TL;DR: The results suggest that substantially shortening treatment courses with stereotactic body radiotherapy does not increase either gastrointestinal or genitourinary acute toxicity.
Journal ArticleDOI
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.
Alison Tree,Peter Ostler,H. van der Voet,William C. Cho,Andrew Loblaw,Daniel Ford,Shaun Tolan,Suneil Jain,Alexander G.R. Martin,John Staffurth,John G. Armstrong,Philip Camilleri,Kiran Kancherla,John Frew,Andrew K Chan,Ian S. Dayes,A. Duffton,Douglas Brand,D. Henderson,Kirsty Morrison,Stephanie Brown,Julia Pugh,Stephanie Burnett,Muneeb Mahmud,Victoria Hinder,O. Naismith,Emma Hall,Nicholas van As +27 more
TL;DR: PACE-B as discussed by the authors , a randomized trial of conventional fractionated or moderately hypofractionated radiotherapy versus Stereotactic Body Radiotherapy (SBRT), was conducted at 35 hospitals in the UK, Ireland, and Canada.
Journal ArticleDOI
PACE: Analysis of acute toxicity in PACE-B, an international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) to conventionally fractionated or moderately hypofractionated external beam radiotherapy (CFMHRT) for localized prostate cancer (LPCa).
Nicholas van As,Douglas Brand,Alison Tree,Peter Ostler,William Chu,Andrew Loblaw,Daniel Ford,Shaun Tolan,Suneil Jain,Alexander S. Martin,John Staffurth,Stephanie Brown,Stephanie Burnett,A. Duffton,Clare Griffin,Vicki Hinder,Kirsty Morrison,O. Naismith,Emma Hall +18 more
TL;DR: Key toxicity outcomes were worst grade 2+ Radiation Therapy Oncology Group (RTOG) genitourinary (GU) and gastrointestinal (GI) acute toxicities, compared by Chi-square test with alpha 0.05 divided between the two measures.
Journal ArticleDOI
Stereotactic radiotherapy with focal boost for intermediate and high-risk prostate cancer: Initial results of the SPARC trial.
Luke Nicholls,Yae-eun Suh,Ewan Chapman,D. Henderson,Caroline Jones,Kirsty Morrison,Aslam Sohaib,Helen Taylor,Alison Tree,Nicholas van As +9 more
TL;DR: Dose escalation to MRI-defined prostate lesions using SABR is feasible and safe and rates of Grade 2 + GU and GI toxicities were low and no biochemical relapse was observed.
Journal ArticleDOI
The PACE trial: International randomised study of laparoscopic prostatectomy vs. stereotactic body radiotherapy (SBRT) and standard radiotherapy vs. SBRT for early stage organ-confined prostate cancer.
TL;DR: The PACE trial is an international multicentre phase III trial, comprising two parallel randomisation processes to assess whether SBRT offers therapeutic benefit in comparison to prostatectomy or standard radiotherapy.